I know this will be unusual for this forum as its a post not criticising another poster, but what happened to the software drug discovery platform that is supposed to underpin DXBs research? It was lauded originally, and supposed to be in the process of being licensed out?
Ok, but to who, and is it generating any revenue? Can't see any revenue attributed to it in recent company reports. Seems to have been forgotten by the company, and the posters here. Never mentioned in recent company updates either.
But I'd like to know what is going on with that, if thats not too much to ask.
Ann: Westar Capital Retained as Corporate Advisors, page-41
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.025(6.67%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.0¢ | $387.8K | 1.079M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 394907 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 15948 | 1 |
View Market Depth
| Last trade - 16.10pm 12/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |